Raloxifene: designer estrogen for preventing postmenopausal osteoporosis.
Park
L
L
University of Toronto, Ontario.
Evans
M F
MF
D015519:Bone Density; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004311:Double-Blind Method; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004967:Estrogens / Q000008:administration & dosage / Q000819:agonists*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D020849:Raloxifene Hydrochloride; D013997:Time Factors
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004965:Estrogen Antagonists; D004967:Estrogens; D010880:Piperidines; D010919:Placebos; D020849:Raloxifene Hydrochloride; D002784:Cholesterol